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Abstract 
This thesis focuses on exploring fast and controlled drug release from several liposomal 
drug delivery systems including its underlying mechanics. In addition, the construction of a 
pulsed high-voltage rotating electromagnet is demonstrated based on a nested Helmholtz coil 
design. Although lots of different drug delivery mechanisms can be used, fast drug delivery is 
very important to utilize drug molecules that are short-lived under physiological conditions. 
Techniques that can release model molecules under physiological conditions could play an 
important role to discover the pharmacokinetics of short-lived substances in the body. In this 
thesis, an experimental method is developed for the fast release of the liposomes’ payload 
without a significant increase in (local) temperatures. This goal is achieved by using short 
magnetic pulses to disrupt the lipid bilayer of liposomes loaded with magnetic nanoparticles.  
This thesis also demonstrates that pulsed magnetic fields can generate ultrasound from 
colloidal superparamagnetic nanoparticles. Generating ultrasound remotely by means of 
magnetic fields is an important technological development to circumvent some of the drawbacks 
of the traditional means of ultrasound generation techniques. In this thesis, it is demonstrated that 
ultrasound is generated from colloidal superparamagnetic nanoparticles when exposed to pulsed 
and alternating magnetic fields. Furthermore, a comparison between inhomogeneous and 
homogeneous magnetic fields indicates that both homogeneous and inhomogeneous magnetic 
fields could be important for efficient ultrasound generation; however, the latter is more 
important for dilute colloidal dispersion of magnetic nanoparticles. In strong magnetic fields, the 
ultrasound generated from the colloidal magnetic nanoparticles shows reasonable agreement with 
the magnetostriction effect commonly observed for bulk ferromagnetic materials. At low 
magnetic fields, the colloidal magnetic nanoparticle dispersion produces considerable amount of 
  
ultrasound when exposed to a.c. magnetic fields in the 20−5000 kHz frequency range. It is 
expected that the ultrasound generated from magnetic nanoparticles will have applications 
toward the acoustic induction of bioeffects in cells and manipulating the permeability of 
biological membranes. 
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Chapter 1 - Introduction/rationale for drug delivery systems 
 
 1.1 Lipid-based drug delivery system 
 
Lipids represent a broad class of chemicals which include phospholipids, fatty acids, glycerides, 
sphingolipids and sterols. In this class, there are also included all the derivatives and synthetic 
lipid analogs. Currently a wide range of lipids are available with a variety of physical and 
chemical properties. For example, lipids differentiate themselves by their fatty acid contents, 
melting point and solubility in organic solvents. Primarily lipids are dispersed in organic solvents 
due to their amphiphilic nature. In Figure 1 is shown the structural similarity of the lipid bilayer 
with the cell membrane, lipids representing a class of molecules which are well tolerated by 
living organisms.  
 
Figure 1 Bilayer formed from the arrangement of lipids 
 
In their review, A. Khan1 called the liposomes as “a lipid-based vesicular carrier 
systems” which can be easily altered in size, ranging from a 30 nm up to few microns. Formation 
of liposomes is relatively simple, and it only requires a dry film of lipids which is hydrated with 
an aqueous solution. Upon hydration, the lipid film will swallow and lipid vesicles will be 
formed. Due to its simplicity of formation, loading the liposomes with different molecules is 
straight forward. For example, Zhao et al.,2 show a clinical trial in which a doxorubicin loaded 
2 
liposome system is used in treating breast cancer. These lipid-based formulations represent a 
great interest for encapsulation of different payloads. As described above, under certain 
conditions lipids will form liposomes, which consist of a bilayer of lipids arranged in a spherical 
form. As shown in Figure 2, liposomes can encapsulate both hydrophilic and hydrophobic drugs 
due to their structures.  
 
Figure 2 General scheme of liposomes encapsulating hydrophilic and hydrophobic drugs 
 
The ability to transport and deliver throughout the entire biological system water 
insoluble or poorly soluble drugs, demonstrate that liposomes are a versatile drug delivery 
system. Liposomes can be classified based on their size and the number of bilayers they possess. 
Multilamellar (MLV) vesicles contain multiple concentric lipid bilayers while unilamellar 
vesicles (ULV) consist of an aqueous core surrounded by a single double layer of lipids. 
Furthermore, ULVs can be divided into large unilamellar vesicles (LUV) with a diameter 
ranging from 0.05 – 0.25 µm and small unilamellar vesicles (SUV) having a diameter of 0.05-
0.10 µm. 
The versatility of a drug delivery system arises from the ability that the liposomes can be 
modified and altered depending on the properties needed. For example, if one needs a good 
delivery system that can be used in the blood stream, its relatively easy to coat the liposomes 
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with polyethylene glycol (PEG) which will enhance the stability of the vesicles. Mahmud et al.,3 
showed that in the case of curcumin-loaded pegylated liposomes had a good stability up to 24 
hours. In addition, they also presented another key aspect of the liposome carrier systems, which 
is the ability of carrying a highly insoluble molecule (curcumin) through the plasma.  
 
Figure 3 Diagram showing the requirement for an efficient drug delivery systems 
 
A good drug delivery system, is characterized by its ability to encapsulate, transport, and 
deliver the payload to the target (Figure 3). In this regard, it is critical to discuss about the 
protection that liposomes offer to the payload. As stated before, the liposomes can encapsulate 
the payload either inside or into the lipid bilayer which is beneficial to the drug-medium 
interactions. Basically, until the release, there is no interaction between the payload and the 
surrounding medium because the lipid membrane protects the content. The lipid membrane is 
porous and it can be altered in different ways in order to change its characteristics. This is 
necessary for achieving a good protection of the payload, but also it needs to provide an 
accessible way to destroy the membrane for the purpose of delivering the drug. Different 
4 
methods and techniques of delivering the drug will be discussed in depth later, but first I will 
classify the liposomes based on their structure. 
  
 1.2 Common types of liposomes 
 
Liposomes can be classified into numerous categories depending on the physical or chemical 
properties. Physical properties are characterized by size and number of bilayers while chemical 
properties refer to the types of lipids and the chemical alterations made to the lipid bilayer. There 
are numerous types of liposomes presented in the literature but for the purpose of this thesis, we 
will concentrate on the most common liposome used as a drug delivery system. 
Conventional liposomes are prepared from phospholipids and cholesterol, but there is no 
additional protective outer layer or other ligands that will protect the surface of the liposome. 
Cholesterol is added to the mix of lipids in order to strengthen the lipid membrane. The charge of 
these liposome will depend strictly on the lipids used when prepared. The encapsulation of the 
payload is in the interior space of the vesicle, and they were first used to encapsulate doxorubicin 
that targeted the reticuloendothelial system1. In that study, it has been shown that the liposomes 
were able to reduce the circulation time and also prolonged the drug distribution compared to 
conventional systems.  
Ethosomes are liposomes that consist of a hydro-alcoholic core. The unique property of 
the ethosomes is represented by the fact that they can penetrate the skin layer1. Due to the 
alcoholic reservoir that is found in the core of the liposome, they have an increased fluidity and 
stability which increase the ability to penetrate and induce transdermal delivery of the drug by 
enhancing the depth of penetration, distribution and deposition of the payload4. 
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Novasomes represent another type of liposome, formed from polyoxyethylene fatty acids 
monoesters, free fatty acids and cholesterol1 ranging from 100 nm up to 1000nm. The 
distinguished property of these liposomes is that they can encapsulate simultaneously 
hydrophilic and hydrophobic payloads. Novasomes consist of multiple bilayers (up to seven) and 
they can incorporate a large amount of drugs.  
Virosomes are a modified form of the regular liposomes in which the exterior surface is 
modified with fusogenic viral envelope proteins1. These liposomes are used for delivering 
antigens and anti-cancer drugs, however they are prone to low stability and leakage. First 
virosomes were designed to deliver DNA intracellulary while later they were loaded with a 
vaccine. 
Stealth liposomes also called immune-liposomes, are prepared with polyethylene glycol 
lipids. Just like the name suggests, the stealth liposomes, have the ability to “hide” from the 
immune-response of the bio-system. Unlike conventional liposomes, they have a much higher 
survivability rate (half life equals to 24 hours) and with the use of outside bond ligands they can 
reach a specific target. 
pH sensitive liposomes have been designed to deliver the payload in an environment that 
can be manipulated through pH changes. For example, the liposomes are stable at physiological 
pH but the payload is released when they encounter an acidic medium. 
Magneto-liposomes are constituted from a blend of conventional liposomes and a 
ferromagnetic/superparamagnetic material and they release the payload or be site-directed under 
the action of a magnetic field.  
 The advantages and constituents of new generation liposomes are summarized in 
Table 1-1. 
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Type of liposomes Constituent Advantage of liposomes 
   
Conventional 
liposomes 
Phospholipids  
Emulsomes Phospholipids with a solid fat core High loading of hydrophobic 
drugs 
Ethosomes Alcohol and Phospholipids Good transdermal 
penetration 
Genosomes Cationic phospholipids with a functional DNA 
or gene 
Gene/DNA delivery 
Magneto-
liposomes 
Phospholipids blended with ferromagnetic 
nanoparticles 
Effective targeting, in depth 
delivery 
Novasomes polyoxyethylene fatty acids monoesters, free 
fatty acids and cholesterol 
High encapsulation of drugs 
pH sensitive 
liposomes 
dioleoylphosphatidylethanolamine Effective targeting, long 
circulation in plasma 
Stealth liposomes Lipids modified with polyethylene glycol Enhanced biological stability 
Virosomes Lipids modified with fusogenic viral 
envelopeproteins 
Intracellular delivery of 
DNA and anti-cancer drugs 
Table 1-1 Summary of new generation liposomes 
 
Liposomes should be characterized after preparation to be certain that all required 
properties are met when exposing them to the in vitro and in vivo medium. There are a few key 
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features that need to be confirmed before performing an experiment: diameter, size distribution, 
number of bilayers, concentration, and encapsulation efficiency of the payload. The most 
common technique to determine the size of the liposome is dynamic light scattering which 
ensures a rapid and simple way to measure the average size of the liposome bulk. If an accurate 
characterization of the liposomes is necessary, one can use the electron microscopy due to the 
possibility of observing individual liposome, and precisely obtaining information about the 
population of liposomes in the whole sample. To prevent the liposomes from fusing, its common 
to measure the electronic stabilization i.e. surface charge, by zeta potential measurements. It is 
essential to measure the amount of the material encapsulated in the liposome, Buboltz et al.,5 
showed that typically, this is obtained by the destruction of the lipid bilayer (100% release) and 
quantifying the released material. 
For the liposomes to be used in the pharmaceutical industry, they must be sterilized. 
Common methods of sterilization include the terminal sterilization of the final product (steam 
sterilization) or aseptical manufacturing of the liposomes.4 Terminal sterilization is preferred due 
to a higher assurance level of sterility compared to aseptical sterilization procedures. Due to the 
susceptibility of liposomes to physical and chemical degradation, it is challenging to find a 
convenient method of sterilization. Several procedures for sterilization of liposomes are 
filtration, dry heat sterilization, gamma irradiation, steam sterilization, ethylene oxide 
sterilization or ultraviolet sterilization.4 The most effective and common method for sterilization 
of liposomes is filtration due to the fact the no heat is used, therefore the liposomes are not 
subjected to heat degradation or leakage. A drawback of sterilization of liposomes through 
filtration is that the method needs to be performed under aseptic conditions. It is time consuming 
and needs to be performed to the liposomes that are 200 nm or smaller.      
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 1.3 State of the art of lipid-based drug delivery systems 
 
In the recent years of biomedical research, the need for a versatile and effective drug delivery 
platform has increased due to the challenges that diseases like cancer or malaria poses. The use 
of nanotechnology in drug delivery systems has become irreplaceable as the advancement in the 
pharmaceutical industry thrived. Initially, one clear direction for developing a better drug 
delivery system has been approached: the achievement of an improved fractional distribution of 
the payload at the targeted site.6 With the introduction of lipid-based drug delivery systems a 
void has been filled in this field. As lipid-based delivery systems have been effective at 
enhancing the efficacy of the chemotherapeutic agents for cancer treatments,7 novel drug 
delivery platforms are currently being investigated. 
Magnetic Liposomes. The term of magnetic liposomes refers to the fact that magnetic 
nanoparticles (magnetite, maghemite) and the drug, are encapsulated within the liposome. With 
the help of a magnetic field this drug delivery technique can be targeted into the tumor. The 
liposomes are administrated intravenously and with the help of a carefully placed magnetic field 
the liposomes can be concentrated at the tumor site.8 The typical size of the encapsulated 
magnetic nanoparticles is less than 10 nm.  Nabuto et al.,8 showed a study, where magnetic 
liposomes encapsulated with doxorubicin have been intravenously administered to a hamster 
with a limb osteosarcoma. The limb was placed in a magnetic field (0.4 T) and after 60 minutes, 
the concentration of doxorubicin at the tumor site was increased by a factor of 4.   
Redox sensitive liposomes. A high reduction potential difference is present close to the 
cell membrane due to increased number of reducing agents such as glutathione.9 The difference 
in the reduction potential between the extracellular and intracellular mediums should, and can be 
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exploited with the help of redox-sensitive liposomes. To reach the target, liposomes can be 
coated with a ligand conjugated by disulfide bond. The disulfide bond will be destabilized by the 
glutathione when the liposomes enter the intracellular compartment of the cell, thus, the payload 
will be released from the liposome.  
Ultrasound sensitive liposomes. In 2015, the development of echogenic (the ability to 
reflect ultrasound waves) liposomes10 allows the payload to be released via ultrasounds. These 
liposomes contain an emulsion that is vaporizable that results in a high response from the 
ultrasounds.  Javadi et al.,11 showed that eLiposomes, liposomes that have an liquid emulsion of 
perfluorocarbons encapsulated, are ruptured by decreasing the local pressure below the vapor 
pressure of the emulsion. The change in pressure makes the perfluorocarbon emulsion to 
vaporize and the liposomes become sensitive to ultrasounds.  
Enzyme sensitive liposomes. Several enzymes have been found to be overexpressed at the 
tumor site like phospholipase A2, transglutaminase, alkaline phosphatase or matrix 
metalloproteinases12 To exploit this enzyme overexpression, liposomes can be engineered with a 
linker that will be cleavable in the presence of these enzymes. Upon the cleavage of the linker 
the surface of the liposomes will be altered for a better adhesion to the cell membrane. In 2012, 
Zhu et al.,13 presented a system in which a drug delivery method was developed in response to 
the up-regulated matrix metalloprotease 2 (MMP2). The surface of the liposome was 
functionalized with a polyethylene glycol lipid conjugate, and upon reaching the cell membrane, 
the lipid conjugate was cleaved by the MMP2, exposing a cell penetrating peptide which 
enhanced intracellular delivery. 
Liposomes for photodynamic therapy. Photodynamic therapy is a treatment that uses the 
response of a photosensitizing agent upon exposing it, to a certain wavelength of the light. Upon 
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exposure to the light the photosensitizer will generate reactive oxygen species that will kill the 
cancer cells.14 In this type of delivery system, the liposome’s role is to protect the photosensitizer 
from aggregation, improve the concentration, reduced phototoxicity and to improve target 
specificity. This type of therapy is used for treatment of superficial tumors. 
 
 1.4 Combination of nanoparticles and liposomes for drug delivery  
 
Cancer is a leading cause of worldwide death and in order to beat it, researchers have developed 
various strategies, starting with surgery, chemotherapy, radiotherapy, hyperthermia, targeted 
therapy, and even hormone therapy.15 Chemotherapy represents the last resort in fighting cancer, 
but due to the lack of specificity and toxic side effects scientists searched for an alternative 
method to deliver drugs to the tumor site. In chemotherapy, anticancer drug is intravenously or 
orally administrated to the patient. Thus, the dug is systemically circulated throughout the body 
without a special localization to cancer site.16 Nanomedicine represents a new direction that has 
been approached in order to solve the drawbacks of current therapies. Implementation of 
nanotechnology in cancer treatment must provide novel therapeutics while reducing the side 
effects of anticancer drugs to healthy cells. Nanotechnology can improve current treatments by 
the application of different nanovectors such as lipid-based structures, dendrimers, several metal 
nanoparticles, polymers and polymer-drug conjugates.15 The term of nanovectors refers to nano-
scale drug delivery systems. Along with several drug delivery systems, liposomes present a great 
interest in the field of drug delivery. A schematic of nanoparticle-liposome drug delivery system 
is presented in Figure 4. First, the nanoparticles and drugs are encapsulated into liposomes 
(synthesis), following by the liposomes injection into the blood stream (transportation). Finally, 
11 
upon exposure to a nanoparticle sensitive technique, the drug is release at the tumor site 
(delivery).  
 
Figure 4 Schematics of a nanoparticle-liposome drug delivery system 
 
In his dissertation, Matthew Basel, describes two methods for targeting a cancerous 
tumor with the help of a drug delivery system based on liposomes that are sensitive to cancer 
associated proteases.17 In comparison to other drug delivery systems, liposomes allow the 
encapsulation of both hydrophilic and hydrophobic drugs, good biocompatibility, capacity for 
self-assembly and protect the payload from external environment.18 On the other hand, metallic 
nanoparticles have been successfully used in cancer therapies.19 For example, Zhang et al.,20 
showed that ultra-small gold nanoparticles (2.7 nm) doxorubicin conjugated, enter in the 
endocytic vesicles of B16 melanoma cells, resulting in a 20-fold increased toxicity compared to 
the equivalent concentration of doxorubicin. Nanoparticles can improve drug delivery to 
cancerous tumors without the need of localized or specific targeting. Such a phenomena is 
caused by the enhanced penetration and retention (EPR) effect, due to the enhancement of 
extravasation at the tumor site.21 Extravasation refers to the leakage of intravenously injected 
12 
drugs into the extravascular tissue around the tumor site. Other examples of metallic 
nanoparticles used in drug delivery systems are: 
• Neodymium based ultrasmall nanoparticles – used in photothermal therapy22 
• Copper ferrite – used in studies for reducing the viability and damaging the membrane of 
MCF-7 cells (human breast cancer cells)23  
A combinational drug delivery system formed from metallic nanoparticles and liposomes 
might improve the efficacity of the drug delivery system or enhance a fast release of the payload. 
It is possible to combine the liposomes with metallic nanoparticles to improve drug delivery 
systems even further. Several studies have shown that a liposome based drug co-delivery systems 
improve drug’s pharmacokinetics and therapeutic effects while decreasing its adverse side 
effects.15  
 1.5 Means of actuation of liposome based drug delivery systems 
 
Application of nanotechnology for the treatment of cancer or other diseases has led to the 
development of several drug delivery systems based on different technologies.24 Since the 
introduction of liposomes in drug delivery platforms, scientist have searched a way to improve 
the efficacity and active drug targeting of liposomal based delivery systems.25 In this chapter, we 
will discuss the advantages and drawbacks of the latest state of the art delivery systems. 
 
 1.5.1 Enzyme activated drug delivery 
 
Understanding the tumor specific microenvironment changes or variations from the healthy cells, 
represents the key to a specific and targeted drug delivery system.  For this purpose, several 
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enzyme activated systems have been developed with a simple aim: to take advantage of the 
changes that occur in the surrounding microenvironment of the tumorous site. Phospholipase A2 
(sPLA2) is a secretory enzyme that is overexpressed in tumors. The role of PLA2 enzymes in the 
human body is to downregulate cell signals via the cleavage “deactivation” of bioactive 
phospholipids.25 A subtype of PLA2 enzymes, sPLA2 IIA, is suspected to have a role in 
tumorigenesis and metastasis and it is overexpressed in several cancer types, like prostate, breast 
and colon cancer.26 Patients suffering from lung or gastric cancer have an elevated level of 
sPLA2 enzymes of 28% while for patients with liver cancer the percentage increases to 100%.
27  
Utilizing the elevated levels of sPLA2 at the tumor site as a trigger for a drug delivery 
platform can lead to a specific and targeted treatment. Liposomes containing anticancer drugs 
and that were susceptible to sPLA2 have been developed,
25 and the release was precisely 
triggered by the enzyme. Andresen et al.,28 have analyzed various sPLA2 degradable liposomes, 
with different lipid composition (DSPC/DSPG/DSPE-PEG2000) loaded with doxorubicin. After 
5 hours of incubation in a media containing sPLA2 secreted from colon cancer cells, they found 
the release of doxorubicin to be 80%. 
 
 1.5.2 Light activated drug delivery 
 
Light can be used as a triggering method for a drug delivery system due to a high spatial and 
temporal control. The penetration depth of light is largest in the near IR region. Beam diameter, 
intensity and the wavelength of light, can be easily modified to create a unique and versatile 
method for triggering drug release.29 Up to date, several light triggering techniques have been 
developed depending of the type of light used. For example, ultraviolet light is used in 
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isomerization, polymerization, photocleavage or conversion of energy to heat. Visible light is 
used in polymerization, oxidation or energy conversion to heat, while near-infrared light is 
mostly used for the conversion of energy to heat.29 Light activated drug delivery systems can be 
used in two different ways, the delivery system can have a “single use” (the payload is fully 
released upon triggering) or the platform can be switchable (the payload can be switched on and 
off for a stepwise release).30 The whole concept of using light to trigger the release of the 
liposomes’ payload, is based on the fact that light will introduce a structural change in the system 
that will lead to the drug release. 
Lajunen et al.,29 describe a drug delivery system formed from indocyanine green (ICG) 
loaded liposomes and ARPE-19 cells (human retina cells). The internalization of ICG liposomes 
(100 nm) into ARPE-19 cell line was investigated through flow cytometry. Calcein loaded ICG 
liposomes were successfully internalized by the cells and upon exposure to near-infrared light 
(9.7 W/cm2, 2 min) calcein was released into the cells. The fluorescence of the cells showed a 2-
3-fold increase compared to the control sample (sample was not exposed to near-infrared light). 
There are two possible mechanisms for the release of calcein: 1) exposure to light increases the 
temperature and causes leakage in the liposomal wall; 2) the increase in temperature forced the 
fusion of the liposomal membrane with the vesicular walls leading to the delivery of the payload 
into the cytosol. 
Although there are several studies showing drug release via light activation of liposomes 
in vitro,31 it is important to say that light activation drug delivery is not a viable method for 
obtaining drug release from liposomes in vivo, because of the limited transmission of the light 
through the body. The method needs to be significantly developed before it can be a successfully 
drug delivery platform.  
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 1.5.3 “Traditional” focused ultrasound delivery 
 
Ultrasound consist of longitudinal pressure waves that propagate through a medium with a 
frequency higher than the audible ones for the human ear, i.e. higher than 20kHz.32 Ultrasound 
waves can be classified depending on the frequency as low frequency, (20-200 kHz) medium 
frequency. (0.6-3 MHz) and high frequency (>3MHz).33 In medicine, ultrasound is generated 
using piezoelectric transducers, which convert a high frequency alternating current into acoustic 
vibrations.34 Several criteria must be taken into account when choosing the ultrasound frequency: 
penetration depth (frequency of the ultrasound wave is invers proportional to penetration depth; 
1MHz – 10 cm) and the spatial resolution (frequency of the ultrasound wave is direct 
proportional to spatial resolution; used mostly for imaging). Focused ultrasound waves allow the 
deposition of a high energy into a small zone of the body, (usually the size of a rice grain) while 
unfocused ultrasound is used to insonify large tumors.32  
In the recent years, drug delivery systems have been developed to take advantage of the 
fact that ultrasounds are known to induce biological effects like thermal effects, mechanical 
effects and radiation forces.32 Several studies showed that ultrasounds enhanced the uptake of 
drugs in cells and tissues by compromising the integrity of cell membranes (sonoporation).33 
Ultrasound have been also used in liposomal systems with encapsulated drugs, in which the 
release was triggered by the ultrasound at the site of interest.35  
In their study, Myhr et al.,36 analyzed the effects of low frequency (20 kHz) ultrasound 
exposure of liposome (doxorubicin encapsulated) on 144 Balb/c nude mice inoculated with WiDr 
(human colon cancer) cell lines. The results are encouraging, showing for the first time that upon 
exposure to non-hyperthermic ultrasounds, liposomes with encapsulated cytostatic drugs 
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significantly hindered tumor growth. Furthermore, they showed that the synergetic effect 
between the ultrasounds and drugs was larger in the cases where low drug concentration was 
used. Thus, patients for whom chemotherapeutic treatment has a minimal effect may benefit 
from this type of treatment.  
However, the “traditional” ultrasound therapy can be challenging due to attenuation as 
ultrasound travels through bones, soft tissue or air. 
 
 1.5.4 Magnetic drug delivery 
 
As previously discussed, the synergistic effect of co-delivery therapies can enhance the efficacity 
of a drug delivery system, therefore getting closer to defeat cancer. Beside the techniques 
previously presented in this thesis, magnetic drug delivery has been used to improve the 
drawbacks of current delivery systems. Magnetic drug delivery refers to a system which is 
composed of a magnetic field susceptible material and the application of the magnetic field as a 
trigger for drug release. For the treatment of cancer or infectious diseases it is desirable to deliver 
the payload at once after the target has been reached.  
To satisfy the need for a fast and localized delivery, a new delivery system has been 
developed, magneto-liposomes. Magneto-liposomes are a co-delivery system formed from the 
combination of a metallic nanoparticle (e.g. iron oxide) and liposome. The magnetic 
nanoparticles with a diameter that is larger than 10 nm are encapsulated into the aqueous core of 
the liposomes, while nanoparticles with diameter smaller than 5 nm can be entrapped into the 
bilayer of the liposome. Furthermore, the magnetic nanoparticles surface needs to be 
appropriately prepared depending on the localization. For example, nanoparticles incorporated in 
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the aqueous core of the liposome need to be hydrophilic, while for the incorporation in the lipid 
bilayer, they need to be hydrophobic for compatibility purposes with the liposomes.   
Several liposomal drug delivery systems have been developed37 that rely on the slow 
release of their payload. However, fast drug delivery is very important to utilize drug molecules 
that are short-lived under physiological conditions. Currently, for magneto-liposomes systems, 
there are two main mechanistic methods of delivering the drug: AC magnetic hyperthermia38 and 
a pulsed application of the magnetic field.39 The mechanism of hyperthermia is dependent of 
selective tumoral cell heating (41-46 oC) leading to cell apoptosis. Several research groups38 
have used AC magnetic hyperthermia to trigger the release of magneto-liposomes’ payload by 
heating magnetic nanoparticles within the supramolecular nanostructure until either burst or 
(partially) dissolve in the surrounding aqueous medium. Although this approach appears to work, 
it has the disadvantage that the liposomes’ payload may be damaged by the head and the release 
is not instantaneous. This is certainly valid for anticancer drugs like SN-38 and its prodrug 
irinotecan40 and si-RNA40b that can degenerate when heated above 56 oC. Another downside to 
be considered in the mentioned systems, refers to the fact that the release of drugs takes place on 
a minute time scale.  
 
 
Figure 5 Illustration of a typical pulsed magnetic field inducing drug release from 
magneto-liposome. Reprinted with permission from ref.39 Copyright (2014) American 
Chemical Society 
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The versatility of magneto-liposomes systems arises from the method that is used to 
deliver the payload. As stated previously, AC magnetic hyperthermia has been successfully used 
in cancer treatments but with some drawbacks (i.e. slow release of the drug, drugs can be 
damaged by heat). To eliminate the drawbacks of AC magnetic hyperthermia, a new method, 
presented in Figure 5, has been developed, pulsed magnetic field drug release. The method is 
developed for immediate release of the liposomes’ payload without a significant increase in the 
local temperature. This goal is achieved by using the mechanical motion of the magnetic 
nanoparticles that are embedded within either the cores of the lipid bilayers of the liposomes, or 
at the interface between core and bilayer. The application of a strong magnetic pulse induces the 
mechanical motion of the magnetic nanoparticles and locally destabilizes the lipid bilayer and 
causes its collapse, subsequently releasing the liposomes payload. In contrast to the head-induced 
release from magneto-liposomes from AC magnetic fields, the drug release takes place due to 
mechanical motion of magnetic nanoparticles, therefore producing a significantly smaller 
amount of residual heating. 
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 1.5.5 Thesis contributions 
 
Advancements in nanotechnology lead to nanomedicine, that improved the overall cancer 
survival rate because of combinational therapies. The overarching goal of this work, aims at 
providing alternative drug delivery methodology in order to address the shortcomings of existing 
drug delivery systems based on liposomes. Pursuing this goal, I wanted to focus on the following 
aspects of liposomal drug delivery systems in this dissertation:  
 
(1) I will demonstrate the synthesis of liposomes loaded with superparamagnetic 
nanoparticles and model drug molecules (Chapter 2). 
(2) I will present data on building and characterizing electromagnetic coils for the 
generation of strong magnetic fields that can be in liposomal drug delivery (Chapter 2). 
(3) I will show the construction of a pulsed high-voltage rotating electromagnet based on 
a nested Helmholtz coil design, for future use of drug release studies (Chapter 3). 
(4) I will prove and attain fast and controlled drug release from magneto liposomes upon 
exposure to various magnetic fields (Chapter 4). 
(5) I will investigate and clarify ultrasound generation from colloidal iron oxide 
nanoparticles upon exposure to homogeneous and inhomogeneous magnetic fields (Chapter 5). 
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Chapter 2 - Experimental tools and synthesis techniques  
 2.1 General approach to synthesize unilamellar liposomes 
 
Liposomes are produced by the thin-film hydration method coupled with sequential 
extrusion method which is adopted from the Ph.D. thesis of Matthew T. Basel.17 To prepare 
magneto liposomes (Figure 6), 88:1:10 molar ratio of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and cholesterol 
are mixed for total lipid of 10 mg in a round-bottom flask. Then, in order to ensure a 
homogeneous mixture of the lipids, purchased powdered lipids are dissolved in an organic 
solvent (chloroform).  
 
 
Figure 6 (A) TEM image of bare liposomes. (B) TEM image of magneto liposomes. (C) 
TEM image of inside a magneto liposome of image B showing the PtFe nanoparticles. (D) 
HRTEM image of the PtFe nanoparticles from image C. Reprinted with permission from 
ref.39 Copyright (2014) American Chemical Society 
 
 
The solution was then vortexed for 1 min to ensure the even dispersion of the lipids and 
cholesterol. DSPC and DPPC are the phospholipids used to create the lipid bilayer of the 
liposomes, and cholesterol is added for increased stability. Once these compounds have been 
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added, the chloroform is evaporated off at approximately 55 °C. After evaporating the 
chloroform, the sample is placed in vacuum for 1 h. The next step is hydration of the thin-film 
lipid which is carried out simply by adding and agitating an aqueous medium into the thin-film 
of the lipids. Next, the residue is hydrolyzed to which either 125 μL of phosphate buffered saline 
(0.136 M NaCl, 0.0045 M KCl, 0.012 M phosphate- buffered to pH 7.4) or 125 μL of HEPES 
buffered saline (0.136 M NaCl, 0.0045 M KCl, 0.012 M HEPES buffered to pH 7.4), together 
with 838 μL of double distilled water and 37 μL of 3 M NaOH are added to the dried 
phospholipids. During this step, the encapsulation of a defined amount of nanoparticle solution 
(FePt or Fe/Fe3O4), MgSO4 (25 mg), and carboxyfluorescein (25 mg) occurs simply by adding 
the desired amount to the lipid solution. If the nanoparticles are insoluble in water, one should 
mix them with lipid before making the thin film of lipid. 
For control experiments, the same protocol was used, the only difference being the fact 
that no nanoparticles were added. After everything has been added to the lipid/nanoparticle 
solution, the mixture is vortexed for a minimum of 5 min. This creates the multilamellar 
liposomes which are larger than the final desired product (unilamellar liposomes). The next step 
is the freeze/thaw process. The mixture is placed in dry ice for 5 min and then placed in a 50 °C 
water bath for 5 min. This procedure is repeated 10 times. At the end of the process, the solution 
stays in the hot water bath. Next is the extrusion process where the multilamellar liposomes 
become the desired unilamellar liposomes, typically 50−250 nm in diameter. The solution is kept 
at 50 °C and extruded through a 200 nm pore diameter filter 11 times, ending on the opposite 
side from where the liposomes began. The final step is gel filtration in which the unilamellar end 
product is isolated from anything else present in the solution. The separation column is filled 
with a slurry of sephadex and phosphate buffered saline solution. The magneto liposomes are 
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collected in the first fraction from the column during the final separation step. The collected 
fraction of the magneto liposomes is analyzed via dynamic light scatterring resulting in a 
diameter of 200 nm ±30 nm. 
.  
 2.2 Fluorescence based permeability measurements of liposomes 
 
To investigate the permeability of magneto liposomes upon exposure to the magnetic field, a 
drug model molecule 5(6)-carboxyfluorescein (CF), is encapsulated into the liposome. The 
model drug of the investigation, CF, is responsible for the fluorescence emission from thus 
prepared liposomes. CF is a hydrophilic fluorescent molecule and it should be entrapped in the 
core of liposome. CF generates emission fluorescence at around 517 nm. The intensity of CF 
fluorescence gives the amount of free CF in the system. The change in fluorescence intensity is 
measured upon exposure to the pulsed magnetic field. The fluorescence self-quenching decreases 
as the CF molecules come out from the liposomes.41 The steady state fluorescence is measured at 
excitation wavelength 460 nm with 1 nm slits. To calculate the drug release from both control 
liposomes and magneto liposomes, 200 μL of thus prepared liposomes or magneto liposome is 
diluted using 3 mL of PBS buffer. The emission fluorescence spectra of liposomes before 
exposing into pulsed magnetic field, after exposing into 10 pulses of pulsed magnetic field, and 
after the addition of 100 μL of Triton X-100 are recorded. The addition of Triton X-100 
completely releases the CF through vesicle disruption. 
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 2.3 AC conductivity based permeability measurements of liposomes 
 
AC measurements are conducted with a potentiostat capable of conducting AC impedance 
measurements. The electrodes are commercially available carbon-printed electrodes, using three 
electrode configurations. As a first test, the conductivity of MgSO4 is tested for different 
concentrations (Figure 7). Frequency in hertz is displayed on the x-axis, and the amplitude of the 
impedance in ohms is displayed on the y-axis. Impedance is the measure of the maximum volts 
across the circuit divided by the total current across the circuit, and it is inversely proportional to 
conductivity. Therefore, the lowest concentrations have the highest impedance values because 
they are the least conductive. 
  
 
Figure 7 Bode plot of magnesium sulfate at different concentrations. Reprinted with 
permission from ref.39 Copyright (2014) American Chemical Society 
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The black line represents distilled water which ideally would not have any ions at all. The 
red line is the lowest concentration of MgSO4. It is only 1.0 × 10
-5 M, yet there is a significant 
difference between the impedances of the distilled water and the 1.0 × 10-5 M MgSO4. This 
demonstrates how sensitive impedance spectroscopy is to low concentrations of ions. As the 
concentration of MgSO4 is increased, a decrease in impedance or an increase in conductivity, is 
observed. 
 
 2.4 Synthesis of Magnetic Nanoparticles 
 
PtFe nanoparticles (Figure 8), are synthesized via the following procedure described by Chao 
Wang et al.42 Into a three-neck round-bottom flask are loaded 0.015 mol of oleylamine and 0.015 
mol of octadecene and 0.00025 mol of platinum(II)acetylacetonate (Pt(acac)2). This flask is 
purged, vacuumed, and backfilled with argon gas three times, and the temperature is raised to 60 
°C. The solution is allowed to sit there for 10 min and then quickly heated (in less than 5 min) to 
120 °C. Upon reaching 120 °C, 0.00025 mol of iron pentacarbonyl is rapidly injected into the 
flask and the temperature raised to 160 °C and allowed to sit at this temperature for 30 min. 
Particles are then allowed to cool to room temperature and were cleaned using standard 
centrifugation (rinse 3 times hexane/ethanol) and redissolved in hexane.  
 
25 
 
Figure 8 FePt nanoparticles synthesized by Chao Wang protocol42. Reprinted with 
permission from ref.39 Copyright (2014) American Chemical Society 
 
 
Iron nanoparticles are prepared with slight modification of a literature procedure 
described by Lacroix et al.43 A 250 mL, three-necked, round-bottom flask equipped with a 
magnetic stir bar, one cold water cooled jacket condenser on the middle neck and one septum 
and one temperature probe on each of the outer necks is charged with 60 mL 1-octadecene 
(ODE), 0.9 mL oleylamine, and 0.831 g hexadecylammonium chloride (HAD·HCl). The reaction 
system is connected to a Schlenk line through the top of the jacket condenser. The reaction 
mixture is degassed at 120 °C for 30 min with vigorous stirring. After refilled with argon, the 
reaction mixture is heated to 180°C. Three portions of 0.7 mL Fe(CO)5 are injected into the 
reaction mixture via a syringe every 20 min. The reaction mixture is kept at 180 °C for another 
20 min after the last injection and cooled to room temperature naturally. The supernatant is 
decanted, and the iron nanoparticles accumulated on the magnetic stir bar are washed with 
hexane and ethanol. The product is dried in vacuum and stored at room temperature for further 
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use. Based on iron, the yield of the reaction is 95%. Three coatings of Fe/Fe3O4 will be used by 
attaching either hydrophilic, amphiphilic, or hydrophobic peptide sequences. HIV-1 Tat-(48−60) 
(GRKKRRQRRRPPQ) will serve as the hydrophilic oligopeptide. In its monomeric form, it is 
known to bind to double-layers. Penetratin will be employed as the amphiphilic oligopeptide 
(RQIKIWFQNRRMKWKK), and membrane translocating sequence peptide 
(AAVALLPAVLLALLP) will be used as the hydrophobic oligopeptide. 
Core/shell magnetic Fe/Fe3O4 nanoparticles were first coated with dopamine, through 
which free NH2 groups were introduced into the surface of nanoparticles (Figure 9). Next, 
reacting the C-terminal of hydrophilic, amphiphilic, or hydrophobic peptide sequences with the 
NH2 groups resulted in the peptide functionalized magnetic nanoparticles.  
 
 
Figure 9 (Left) Schematic view of the iron oxide nanoparticles coatings for the release 
studies presented in this thesis. The peptide sequence modification allows modifying the 
hydrophobicity of the nanoparticle coating. (Right) TEM image of core/shell magnetic 
Fe/Fe3O4 nanoparticles. Reprinted with permission from ref.39 Copyright (2014) American 
Chemical Society 
 
 
Briefly, 10 mg of dopamine-coated Fe/Fe3O4 nanoparticles were dispersed into 2 mL of 
dry DMF, 5 mg of peptide sequence, 0.6 mg of EDC, 0.3 mg of DMAP were added to the 
suspension sequentially. After brief sonication, the reaction mixture was swirled vigorously at 
room temperature for 12 h. Magnetic nanoparticles were collected by centrifugation (10000 rpm, 
5 min), and washed with DMF (2 mL × 3 times) and methanol (2 mL × 3 times). The 
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nanoparticles were finally dried under vacuum and stored under argon for liposome loading. The 
commercial 10 nm iron oxide nanoparticles used in the ultrasound studies were purchased from 
Ferrotec EMG series, and they are water-based ferrofluid type EMG 607 stabilized with cationic 
surfactant. 
 
 2.5 Construction of pulsed electromagnet for drug release studies 
 
In 1924, the first pulsed magnetic field, close to 50 T, was developed by P. Kapitza from his lead 
acid storage battery through 1 mm bore, and he was optimistic about obtaining 200−300 T if 
adequate financial means became available.44 Pulsed magnets are used for two reasons: they can 
provide the highest fields and they can be made to fit a moderate budget. The generation of 
pulsed magnetic field is important for several activities in the area of physical sciences. The 
basic components of a pulsed magnetic field are capacitor bank (C), power supply (V), spark gap 
(also called thyratron switch), inductor (L), and resistors (R). Basically, a pulsed magnetic field 
circuit is an RLC (Resistor−Inductor−Capacitor) circuit. A simple schematic diagram for the 
pulsed magnetic field is shown in Figure 10.  
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Figure 10 (Left) Experimentally determined pulse magnetic field from Faraday rotation of 
water. The inset shows the picture of the helical beryllium copper coil used in the 
experiments. (Right) Schematic circuit diagram of the pulsed magnetic field apparatus. 
Reprinted with permission from ref.39 Copyright (2014) American Chemical Society 
 
 
The capacitor bank is charged with a power supply. When the charged capacitor bank is 
discharged through the inductive coils for a short time, electric energy is transformed into 
magnetic energy.45 The production of a suitably shaped magnetic field requires a current to pass 
through a coil, but choosing the parameters of the coil is nontrivial because of the trade-off 
between the magnetic field strength, the field homogeneity, and the inductance of the coil. 
Increasing the number of turns of the coil increases the field strength for a given current, and 
increasing the diameter of the coil provides a larger region of the field uniformity but decreases 
the field strength. An increase in either the coil diameter or number of turns causes an increase in 
the inductance of the coil, and so for maximizing the rate of field switching, the number of turns 
and coil diameter should be minimized.46 A series of resistors controls the charging current. The 
value of π(LC)1/2 gives the duration of the pulse.47 The pulsed magnet constructed for this work 
consists of a capacitor bank of 77.3 μF of Maxwell Laboratories which is charged by a power 
supply/charger of Lumina Power, Inc. The power supply uses 100−240 V AC-50/60 Hz input 
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and output of 10 kV@500 J/s in continuous operation. All the experimental operations are 
controlled by the computer programmable controller. The overall discharge energy can be 
calculated using the expression 1/2CV2. Principally, the discharge of the capacitor bank tends to 
be critically damped which implies R =2 x (L/C)1/2. The spark gap is the major resistance in the 
circuit, and most of the energy is dissipated through the spark gap during discharge and the 
remaining, negligible, energy is used in the Joule heating of the circuit.47 A small spark gap gives 
the necessary resistance for the critical damping. Theoretically, the capacitor bank needs to be 
charged to cross the breakdown voltage of the spark gap. The breakdown voltage is the minimum 
voltage that causes a portion of insulator to become electrically conductive and complete the 
electric circuit. In these experiments the spark gap is fixed to approximately 2 mm and is 
triggered by using a high voltage trigger pulse generator.  
The strength of the magnetic field applicator is measured via the Faraday rotation of an 
optical material with known optical constant.47 The strong magnetic field induces birefringence 
of an optical material. Rotation of the plane of polarization of a linearly polarized light is 
proportional to the amount of magnetic field according to θ = υBl where υ is Verdet constant of 
the material, B is the magnetic field, and l is the optical path length. The magnitude of Faraday 
rotation of optical materials is linearly proportional to the amount of magnetic field, which is 
utilized in calibrating the pulsed magnetic field for the experiments described in this thesis. For 
the calibration of magnetic fields, either borosilicate glass or water is used with a known optical 
path length. The Faraday rotation constant (Verdet constant) of these materials are published in 
the literature. A linearly polarized 632 nm HeNe laser is passed through the water or borosilicate 
glass sample. The exiting laser beam passes through an analyzer (calcite prism) oriented 45° 
relative to the orientation of the linear polarized light, which allows splitting the laser into two 
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equal intensity beams that are projected on a balanced photodiode (model 2307 large-area 
adjustable-gain balanced photoreceivers from Newport Inc.). The photoreceiver is placed far 
from the magnetic field to minimize any electronic interference from magnetic fields directly 
influencing the signal on the photoreceivers. When the magnetic field is present, the rotation of 
magnetic field appears as a positive or negative signal (depending on the direction of the 
magnetic field) on the oscilloscope from the balanced photodiode. On the basis of the 
characteristics of the photoreciever, the optical power difference and the magnitude and direction 
of the Faraday rotation signal are calculated. Comparing the measured signal with the value from 
the faraday equation of the material, the magnetic field is calculated. For the drug release studies, 
the peak strength of the magnetic pulse remained at approximately 3 T. The actual magnetic field 
profile from faraday measurement is shown in the inset of Figure 10.  
 
 2.6 Construction of Helmholtz and anti-helmholtz pulsed electromagnets for 
ultrasound measurements  
 
Two identical electromagnetic coils (Helmholtz and anti-Helmholtz configuration) are 
constructed with opposite windings to produce homogeneous and inhomogeneous magnetic 
fields for ultrasonic experiments. These magnetic fields are used to help assess the ultrasound 
generated from single domain superparamagnetic nanoparticles. The first coil, also called the 
anti-Helmholtz coil, is shown in Figure 11-A,B. Figure 11-A shows the schematics of the coil 
winding of the anti-Helmholtz coil, and Figure 11-B shows the picture of the coil. The coil is 
constructed from alternatingly stacking copper and mica disks similar to the construction of 
bitter magnets.  
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Figure 11 (A) Sketch of anti-Helmholtz coil to produce large pulsed magnetic field 
gradient. (B) Picture of the finished electromagnet. (C) Measured magnetic pulse by 
Faraday rotation of Pyrex glass. Adapted with permission from ref.39 Copyright (2014) 
American Chemical Society 
 
 
The anti-Helmholtz coil is optimized to produce a large magnetic field gradient, needed 
for the translational motion of the nanoparticles in the colloidal dispersion. The estimated 
maximum linear magnetic field gradient is approximately 800 T/m. In addition to the anti-
Helmholtz coil, a Helmholtz coil is also prepared with parallel winding that produces 
homogeneous magnetic fields. The magnetic field in the Helmholtz coil is measured via the 
Faraday rotation of a small BK7 glass cylinder placed at the center of the Helmholtz coil. Figure 
11-C shows the measured magnetic fields of the Helmholtz coil from the Faraday rotation of the 
BK7 glass cylinder. Both of the coils described above are integrated with electronics that are 
capable of producing several thousands of ampere current pulse to drive these electromagnetic 
coils. In the experiments, the initial coil current is kept constant throughout the experiments. The 
electronics are based on trigger discharged using a spark gap, which limits the lowest magnetic 
fields in the pulsed magnet field generator to several tesla. For coupling and measuring the 
generated ultrasound, one end of a 1 m long glass capillary tube filled with the colloidal 
dispersion of magnetic nanoparticles in water is inserted into the coil and the other end of the 
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capillary is mounted against an ultrasonic sensor (Benthowave, BII 7011 hydrophone). The 
sensitivity of the hydrophone is −198 dB μV/Pa (194.6) with a cutoff frequency of 60 kHz. The 
magnetic fluid used in these experiments is composed of Ferrotech EMG 607 iron oxide 
nanoparticles dissolved in water with the help of proprietary cationic surfactant. The size of the 
particles is 10 nm in diameter with an average magnetic moment of 110 G (saturation 
magnetization 0.011 T), viscosity <5 mPa x s, and a density of 1.1 × 103 kg/m3 at room 
temperature. These particles are stabilized with ionic surfactant that ensured that the particle did 
not aggregate during the experiments. The concentration of the ferrofluid is 2 vol %, which has 
been further diluted for the experiments yielding a volume percent stock solution. The stock 
solution is further diluted for the concentration-dependent studies presented in this thesis. 
 
 2.7 Small amplitude AC magnetic field coils for ultrasound measurements 
 
Small amplitude AC magnetic field coil setup consists of a setup of two coil pairs (Helmholtz or 
anti-Helmholtz configuration) wired with braided and insulated wire for better high-frequency 
response. Between the layers of windings of the coil, a layer of parafilm is used to dampen the 
noise from the movement of the wires. A sketch of the experimental setup is shown in Figure 12.  
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Figure 12 Sketch of the experimental setup used to detect frequency dependent ultrasounds 
from AC magnetic field in homogeneous and inhomogeneous magnetic fields. Adapted with 
permission from ref.48 Copyright (2016) American Chemical Society. 
 
A frequency generator is used to generate continuous sinusoidal wave that is further 
amplified to produce sinusoidal magnetic fields at variable frequency in the coil pairs. Between 
the coil pair, a glass tube is inserted filled with the MNP dispersion. At the end of the glass tube 
a broad frequency response (10−500kHz) hydrophone (BII-7043 Directional Broadband 
Hydrophone) is inserted. The signal from the hydrophone is amplified with a low impedance 
voltage preamplifier and digitized with a 2M sample/s 16 bit DAQ board. The time-domain 
signal is Fourier filtered so that only the signal at the drive frequency is detected and recorded on 
the computer. For each measurement, the background signal of water was also collected and 
subtracted from the data presented in this thesis. The solution of proprietary surfactant is also 
tested for ultrasound generation, and it has showed the same amount of ultrasound as the water 
produced. In order to ensure uniform power transfer by the broadband amplifier, the frequency-
dependent current has been measured with a current sensor (Rogowski coil). To remove the 
frequency-dependent response of the hydrophone, the data are normalized to the frequency 
response of the hydrophone from the 10 to 500 kHz frequency range. 
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Chapter 3 - Nested Helmholtz coil design for producing 
homogeneous transient rotating magnetic fields 
 
 3.1 Introduction 
 
Rapidly changing magnetic fields are utilized in many areas of science and engineering. In the 
field of life science, one important area where magnetic fields are utilized is the field of magnetic 
hyperthermia,49 where the alternating or rotating magnetic fields are utilized to produce heat in 
the sample via Neel or Brownian relaxation of magnetic nanoparticles.50 Generally, magnetic 
nanoparticles can produce useful heat on the order of a few 100 W/g.49, 51 Recently, Lee et al.,52 
have shown that if the exchange interaction of the magnetic nanoparticles is used, the number 
can reach 1000 W/g quantities. Recently, Sharapova et al., have shown that by using rotating 
magnetic fields instead of alternating magnetic fields, the heating efficiency of magnetic 
nanoparticles has increased significantly.53 In traditional magnetic hyperthermia, the magnetic 
field used is a low amplitude sinusoidal magnetic field.49 In general, the produced heat is capable 
of destroying cancer tissue or releasing drug molecules from liposomes39 for targeted delivery. 
However, there are several challenges of this technology so that it reaches its full potential. The 
required nanoparticle concentration for effective elimination of cancer tissue needs to be on the 
order of several mg/ml to reach needed 42-45 ºC temperature.38, 54 In addition, magnetic 
hyperthermia treatments last for several minutes and hours. A more effective way to destroy 
cancer cells is to utilize the nanoparticles as little magnetically driven drill bits. The mechanical 
force55 can potentially be more effective in eliminating cancer cells if the lipid bilayer can be 
punctured.56 Recent results have shown57 that cancer cells are more deformable than healthy 
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cells, which could be utilized in selective cancer cell destruction if combined with mechanical 
force from rotating or twisting magnetic nanostructures as a result of external magnetic stimuli. 
In order to rotate magnetic nanoparticles on the order of 10 to few tens of nanometer size scale, 
the magnetic field needs to be increased to overcome the thermal motion of the particles. The 
required rotating magnetic field strength to manipulate magnetic nanoparticles on the 10-30 nm 
diameter range is on the order of a few hundred millitesla. A simple way to generate rotating 
magnetic fields is via a pair of Helmholtz coils arranged perpendicularly. These designs are 
widespread and can produce magnetic fields that are few millitesla. Increasing the magnetic field 
beyond this point is challenging because the continuous current can result resistive heating which 
requires significant amount of cooling. Cooling of the coils can be facilitated at larger facilities 
such as the National High Magnetic Field facility. However, the laboratory use of these strong 
rotating magnets without cooling is desirable for life science based research. In this chapter, a 
low duty cycle nested Helmholtz coil system is described. It is capable of producing strong 
rotating magnetic pulses without the need of significant cooling. 
 
 3.2 Construction of nested Helmholtz coils  
 
Traditionally, Helmholtz coils are used to generate uniform homogeneous static and alternating 
magnetic fields in a relatively large volume. The Helmholtz coil design is also used to produce 
homogeneous rotating magnetic fields when two or three coils are nested within each other. 
Manipulating the currents inside these coils allows the production of static and rotating magnetic 
fields in the three-dimensional space. Unfortunately, the traditional wire coiling used in 
Helmholtz coils has its limitation in increasing the strength of the magnetic fields. There are 
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several design challenges of producing strong rotating magnetic fields in a relatively large 
volume. Early on, Bitter58 developed a design based on stacking of concentric discs that 
minimizes the forces acting on the coil. The current density in traditional solenoid type coils is 
constant, while in the Bitter coil designs, the current density falls with 1/r producing a more 
favorable condition for high magnetic fields. The additional advantage of the bitter coil design is 
that it distributes the mechanical stress from the Lorentzian force more evenly than in the wire 
coiled solenoid and also allows efficient cooling if holes for liquid coolant are introduced in the 
bitter disks.  
 
Figure 13 (a) Assembly of the bitter disks. (b) Dimensions of the bitter disk used to produce 
the nested Helmholtz coil. (c) Top view of the Helmholtz coil indicating the directions of the 
magnetic field produced in this paper. (d) Perspective picture of the nested Helmholtz coil 
without the Teflon insert. Reprinted from ref. 59 with the permission of AIP Publishing. 
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In this thesis, a merged of the Bitter design of electromagnet (Figure 13) is used, to form 
a 2D Helmholtz coil system for producing rotating magnetic fields. The Bitter disks are 
manufactured from copper-beryllium alloy to increase the tensile strength of the coil material to 
resist the mechanical stress from the Lorentzian forces. The tensile strength of copper is 220 
MPa while the copper-beryllium used in this work has a tensile strength of 820 MPa. The 
conductivity of copper-beryllium (1/2 HT tempered C17410 alloy) is 50% of the conductivity of 
copper. The Bitter disks are electrochemically plated with silver, which further increases the 
conductivity of the coils and reduces the contact resistance. The bitter disks are separated by 
mica sheets and sandwiched between the silver coated copper end plates. The packing order and 
the assembly of the bitter disks are also shown in Figure 13. The two parts of a single Helmholtz 
coil are held together by brass rods that are insulated from the electrical components of the coils. 
The spacers between the two parts of the coil are manufactured from high conductivity copper 
rods. These rods are also silver plated for optimal conductivity. The smaller nested Helmholtz 
coil is assembled with the help of a Teflon insert, which secures the smaller coil inside the larger 
coil. The Teflon insert can be rotated with the inner coil so that the main rotating axis of the 
rotating magnet can be changed.  
 
 3.3 Results and discussion  
 
The nested Helmholtz coils are calibrated with the help of 60 Hz alternating current from the 
electrical outlet. 12A RMS current is passed through both of the coils, and the magnetic fields of 
the two coils are measured with a low frequency AC Gauss meter. The output from the Gauss 
meter has been recorded and shown in Figure 14.  
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Figure 14 The graph shows the measurement of the magnetic field of the nested Helmholtz 
coils from low frequency alternating current from the electrical outlet. Reprinted from ref. 
59 with the permission of AIP Publishing. 
 
The results from Figure 14, show that in order to achieve the same magnitude magnetic 
fields at the center of the two coils for the circular polarized fields, approximately twice as much 
current has to pass through in the larger coil than in the smaller coil. In these experiments, the 
current in the larger coil is increased by using higher discharge voltage in that coil. By careful 
choice of the number of disks used in each coil, the same amount of magnetic fields can be 
achieved with the same amount of current. The data in Figure 14 also allows calibrating the 
Rogowski coils used in the high voltage experiments. The rotating magnetic field is produced by 
discharging high voltage capacitors via the coils of the Helmholtz magnet. The circuit design is 
shown below, in Figure 15 for a single Helmholtz coil. Two identical circuits are used to control 
the magnetic field independently from each of the nested Helmholtz coils. One of them is shown 
in Figure 15. The capacitor is discharged with the help of a homemade triggered spark gap as 
shown in Figure 15. The trigger pulse is a high frequency 0.5 J 20 kV pulse with a duration of 
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500 ns that initiates the trigger after charging the main capacitor. The high frequency current is 
monitored by a homemade Rogowksi coil, which produces voltages proportional to the dI/dt in 
each coil. The voltages are measured by attenuated probes and recorded by an oscilloscope.  
 
 
Figure 15 (a) Schematics of charging and discharging circuit of a single coil for nested 
Helmholtz coil design. (b) Picture of the homemade spark gap with adjustable gap. 
Reprinted from ref. 59 with the permission of AIP Publishing. 
 
 
The signal is then integrated to produce the current response of the coils. The two 
independent discharge circuits for each of the Helmholtz coils are connected via a digital 
transistor-transistor logic (TTL) timing box, which allows precise control of the magnetic pulses 
with respect to each other. The TTL pulses are used for timing signal to trigger the spark gaps of 
each coil independently. 
The magnitude of the magnetic field applicator is also measured via the Faraday rotation 
of an optical material, such as water or borosilicate glass, with known optical constant (Figure 
16).47 This procedure is necessary to ensure that the electrical sensor properly functions at both 
low and high magnetic fields. The optical measurement of the magnetic field of the coils is as 
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follows: The strong magnetic field induces birefringence of an optical material. The induced 
birefringence of the material rotates the plane of polarization of a linearly polarized light.  
 
 
Figure 16  LEFT: (a) Current signal from the two coils of the nested Helmholtz coils with 
various time delays. MIDDLE: (b) Direct signals from the Rogowski coils for the inner and 
outside Helmholtz coil from 26 simultaneous discharges. RIGHT: (c) Histogram of the 
timing jitter of the inner and outside coil firing from 26 shots. Reprinted from ref. 59 with 
the permission of AIP Publishing. 
 
 
The rotation angle (Θ) varies according to Faraday equation: Θ = 𝜈𝐵𝑙, where 𝜈 is Verdet 
constant of the material, B is the magnetic field, and l is the optical path length. The magnitude 
of the Faraday rotation of optical materials is linearly proportional to the amount of magnetic 
field, which is utilized in the calibration of pulsed magnetic fields for the experiments described 
in this chapter. For the calibration of magnetic fields, water is used with known optical 
pathlength (1 cm). The Faraday rotation constant (Verdet constant) of these materials is 
published in the literature.60 A linearly polarized 632 nm HeNe laser is passed through the water 
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or borosilicate glass sample. The exiting laser beam passes through an analyzer (calcite prism) 
oriented 45º relative to the orientation of the linear polarized light, which allows splitting the 
laser into two equal intensity beams that are projected on a balanced photodiode (Model 2307 
Large-Area Adjustable-Gain Balanced Photoreceivers from Newport, Inc.). The photoreceiver is 
placed far from the magnetic field to minimize any electronic interference from magnetic fields 
directly influencing signal on the photoreceivers. When the magnetic field is present, the rotation 
of magnetic field appears as positive or negative signal (depending on the direction of the 
magnetic field) on the oscilloscope from the balanced photodiodes. Based on the characteristics 
of the photoreciever and the optical power difference, the magnitude of the Faraday rotation 
signal is calculated.  
 
 
Figure 17 (a) signal of the current through Rogowski sensor (b) optical measurement of the 
Faraday rotation of water placed inside the coils (c) current/magnetic field (d) magnitude 
and direction of magnetic fields inside the coils for the rotating magnetic fields. Reprinted 
from ref. 59 with the permission of AIP Publishing. 
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By comparing the measured signal with the value from the Faraday equation of the 
material, the magnetic field is calculated. In Figure 17, the magnetic field of coil is measured via 
electronic sensor from the Rogowski coil (a) and the measurement of the Faraday rotation (b) of 
water placed inside the coils. For this calibration procedure, only one of the coils is fired. The 
direction of magnetic field is parallel to the 632 nm laser used for the Faraday measurement. The 
integrated Rogowski signal (c) is linearly proportional to the signal from the optical 
measurement (d). After calibration, the signals from the two Rogoswki sensors allow monitoring 
the magnitude and direction magnetic fields inside the coils for the rotating magnetic fields. 
Figure 17 demonstrates that the signal from the Rogowski sensor and the optical 
measurement are linearly proportional. Therefore, both measurements can be used to 
evaluate/calculate the magnetic fields of the coils. In the experiments below, the signals from the 
Rogowski coils are used as an indicator of the magnetic field strength.  Figure 16(a) shows the 
effect of changing the delay between the magnetic pulses on the two different coils, which results 
in different shaped magnetic fields. Changing the timing, the coils can produce linear alternating 
magnetic fields or rotating magnetic fields. Figure 17(b) shows the direct output from the 
Rogowski coil pairs fixed at a given time delay. This signal is integrated to obtain the current 
signal as described earlier. The direction of the rotating field can be also manipulated by 
changing the initial direction of the current in the coils resulting in left or right rotating magnetic 
fields. The maximum discharge of the capacitors used in the experiment is 10 000 V, which 
corresponds to 2850 J of energy. In a single shot, the maximum calculated temperature increase 
of the coil from this energy is 1.6 ºC based on the weight of the copper coils and its heat 
capacity, but in reality, it is probably much less than that since this simple estimate does not take 
the weight of the cables and the capacitor into account.  
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The measured rotating magnetic field amplitude is 200 mT at full discharge (10 000 V 
charge for the larger coil). This is about 2.5 times less magnetic field than what is calculated 
from modeling the discharge circuit and comparing the current with the data from Figure 14. 
With careful optimization of the contact points in the coils, the current can possibly be further 
increased, resulting in better agreement between the theory and practice. Timing of the magnetic 
pulses is important so that the desired rotating fields can be produced. The data on the time 
reproducibility (Figure 16), of the magnetic pulses indicate that the jitter of the triggering in this 
system is relatively low. The timing jitter of the relative trigger remains under 1 μs,61 which 
allows accurate timing to produce rotating fields for the few tens of kilohertz underdamped 
magnetic pulses.  
Finally, it is important to match the inductance of the coils to produce pulses where the 
current and magnetic pulses remain in phase for the entire duration of the rotating magnetic field. 
This is demonstrated in Figure 18, which shows two separate cases. When the inductances of the 
coils are not matched, the various time delays will result in “scrambled” magnetic pulses. 
 
Figure 18  LEFT unmatched Helmholtz coil RIGHT matched Helmholtz coil. Reprinted 
from ref. 59 with the permission of AIP Publishing. 
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When the inductances of both coils are matched with the help of installing additional 
cable length to one of the coil circuits, the magnetic pulses become identical in both coils, which 
yield the desired rotating magnetic pulses. The magnitude of the rotating magnetic field is 
calculated from the current measurements from the Rogowski coils during the high voltage 
discharge. In order to test the homogeneity of the rotating magnetic field, calculation is 
performed by using finite element method (FEM) implemented with COMSOL Multiphysics 
(Burlington,MA). This 3D model includes two pairs of coils, with the larger coil centered on the 
y-axis, and the smaller coil centered on the x-axis. The model specifies a current density on each 
coil (out of phase) and solves for the magnetic vector potential and field strength at 100 kHz.  
Figure 19 illustrates the homogeneity of the calculated rotating magnetic field amplitude 
(log(H)) for a 100 kHz continuous operation of the in different planes for the nested Helmholtz 
used in the experiment. The calculation shows that the rotating magnetic field is uniform in all 
directions in the center of the nested Helmholtz coils.  
 
 
Figure 19 Calculated rotating magnetic field amplitude (log(H)) for a 100 kHz continuous 
operation of the in different planes for the nested Helmholtz used in the experiment. r is the 
radius of the smaller inner coil and R is the radius of the larger outer coil. Reprinted from 
ref. 59 with the permission of AIP Publishing. 
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The modeled region is discretized with an inhomogeneous tetrahedral mesh, including 81398 
elements. A frequency domain iterative solver (geometric multigrid) is used to compute the 
magnetic field strength at all points in the simulation domain. The variation of the magnetic field 
amplitude inside the inner coil is few percent relative to the absolute magnitude of the magnetic 
field. The calculation presented above is shown for the idealized 2D Helmholtz coil. 
The dimension of experimental coils used here shows a few percent deviation from the 
idealized Helmholtz coil; with careful adjustment of the manufacturing process, the coil can very 
closely approximate the idealized 2D Helmholtz coil.  
 
 3.4 Conclusions 
 
The construction and operation of a novel Helmholtz are demonstrated to generate strong 
rotating magnetic field. The design shows scalability by manipulating several factors: increasing 
the number of plates used to construct the coils, reducing its dimensions, and increasing 
discharge voltage. The nested Helmholtz coil design could also be used in magnetic hypothermia 
experiments where minimizing the resistive heating is important at high frequencies due to the 
skin effects of the current at several tens of kilohertz. 
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Chapter 4 - Pulsed Magnetic Field Induced Fast Drug Release from 
Magneto Liposomes via Ultrasound Generation 
 
 4.1 Introduction 
 
Liposomes were first described in 1961 (published 196462) by Alec Bangham. Liposomes (and 
the payload that they have trapped inside during formation), can be separated from smaller 
molecules simply by gel filtration or dialysis, making them very useful delivery agents.63 
Liposomes are stable in blood, not releasing their contents,64 and when incubated with plasma 
constituents, they retain their spherical shape.65 Liposomes made from L,α-
dipalmitoylphosphatidylcholine (DPPC) are widely used for the intravenous delivery of drugs, 
because they are not prohibitively expensive and feature suitable biophysical properties. The 
higher phase transition temperature (Tm) of DPPC is 314 K. At T > Tm liposomes can be filtered 
through porous membrane filters, which make spherical unilamellar liposomes with a very small 
polydispersity available.66 The fast removal of the liposomes by the macrophages and monocytes 
of the reticuloendothelial system can be prevented by attaching a polyethylene glycol coating to 
the outside of the liposome.67 Polyethylene glycol apparently creates a steric block around the 
outside of the liposome that does not interact with recognition molecules. Since the polyethylene 
glycol does not interact with recognition molecules and it prevents the recognition molecules 
from reaching the liposomal surface, the liposomes are widely ignored by the reticuloendothelial 
system. The liposomes prepared this way (liposomes coated in polyethylene glycol) have come 
to be known as stealth liposomes.67 To date, several liposomal drug delivery systems have been 
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developed (e.g., Nicoderm and others)37 that rely on the slow release of their payload. However, 
for the treatment of cancer or infectious diseases, it is certainly desirable to deliver the payload 
(drug) at once after the target has been reached. As stated in chapter 1, AC-magnetic 
hyperthermia was used to trigger the release of magneto liposomes’ payload by heating magnetic 
nanoparticles until the liposomes either burst or dissolve in the surrounding aqueous medium.38 
The main disadvantage of AC-magnetic hyperthermia is that the payload can be damaged by heat 
and the release is not fast.  In this chapter, a method is presented for the immediate release of the 
liposomes’ payload without a significant increase in (local) temperature (less than 2-3 oC). This 
goal is achieved by using the mechanical motion of the magnetic nanoparticles that are 
embedded within either the cores of the lipid bilayers of the liposomes, or at the interface 
between core and bilayer. 
The liposomes used here feature comparatively low diffusion coefficients. Without an 
external stimulus, they will retain their payload for extended periods of time.68 To meet this 
challenge, the cholesterol content of their lipid bilayers is adjusted. The mechanical motion of 
the magnetic nanoparticles locally destabilizes the lipid bilayer and causes its collapse and the 
subsequent release of the liposomes’ payload. In contrast to the heat-induced release of drug 
from magneto liposomes from AC magnetic fields, the drug release takes place due to 
mechanical motion of magnetic nanoparticles, therefore producing a significantly smaller 
amount of residual heating. The successful application of the mechanical force on the 
nanoparticles to create controlled disruption in a lipid bilayer places some limits on the 
nanoparticles and magnetic fields that can be used in the experiments. 
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 4.2 Results and discussions  
 
 4.2.1 Liposome Release Studies with MgSO4 
 
The triggered drug release of the magneto liposomes is tested via the release of conductive 
MgSO4 from the liposomes upon exposure to pulsed magnetic fields. In Figure 20, a Bode plot is 
presented, containing the data from liposomes and HEPES (4-(2-hydroxyethyl)-1-piperazine 
ethanesulfonic acid) buffer are in solution. 
 
 
Figure 20 Bode plot of a magneto liposome solution before and after the application of 
magnetic fields. Addition of TRITON X-100 destroys the liposomes and releases all the 
MgSO4. Reprinted with permission from ref.39 Copyright (2014) American Chemical 
Society. 
 
 
The black line in Figure 20 represents the liposomes, which contain superparamagnetic 
nanoparticles and MgSO4, mixed with HEPES Buffer. Then the magneto liposomes were 
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exposed to the strong pulsed magnetic field pulses 10 times. The green line represents the 
magneto liposomes and HEPES buffer after exposure to the magnetic field. As expected, there is 
a decrease in impedance (increase in conductivity) because at least some of the liposomes 
released their payload of MgSO4. The red line is the magneto liposomes after exposure to Triton 
X-100. Triton completely destroys all of the liposomes; however, it also contributes to the 
conductivity. To remove any side effects from the contribution of Triton X-100 to the overall 
conductivity, the magneto liposomes are also destroyed with a sonic dismembrator. After the 
sonication, the sample is left to equilibrate with room temperature for 10 min to remove the 
temperature-dependent bias of the conductivity measurement. The results are summarized in 
Table 1, which shows the MgSO4 release from magneto liposome after application of 10 
magnetic pulses. 
 
 Before 
magnetic 
pulse 
After 
magnetic 
pulse 
After 
sonication 
Percent 
release 
Average  
Liposome 1 5676 4740 3635 48.5% 47.7±1.9% 
Liposome 2 4786 4325 3782 49.2%  
Liposome 3 5459 4734 3802 45.6%  
Control 1 4129 4177 3496 -1.2% -9.5±8.3% 
Control 2 3521 3523 3243 -9.5%  
Control 3 3971 3709 3338 -17.8%  
Table 4-1 Summary of AC Impedance Measurements of Magneto Liposomes Exposed to 10 
Magnetic Pulses. Reprinted with permission from ref.39 Copyright (2014) American 
Chemical Society. 
 
50 
The individual values show the resistance of the solution at 214 Hz and the concentration 
of the MgSO4 is calculated from a formula obtained by fitting the MgSO4 calibration curve 
(Figure 7) (CMgSO4 = ((σ-0.00031)/0.000844)2). Here σ is the conductivity of the sample at 214 
Hz expressed in 1/ohm. The control liposomes do not contain magnetic nanoparticles. 
In addition to the data presented in the Table 4-1, experiments are also conducted to 
assess how many pulses are needed to release the MgSO4 from the magneto liposomes. Figure 21 
shows the impedance measurement of magneto liposome solution following exposure to single 
magnetic pulses. 
 
 
Figure 21 Impedance changes of the magneto liposome solution upon exposure to 
subsequent magnetic pulses. Reprinted with permission from ref.39 Copyright (2014) 
American Chemical Society. 
 
 
 This measurement indicates that a single magnetic pulse releases a significant 
portion of the MgSO4 from the liposome. The magnetic pulses did not produce any noticeable 
heating of the magneto liposomes. 
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 4.2.2 Liposome Release Studies with 5(6)-Carboxyfluorescein Dye. 
 
The typical fluorescence emission spectra are shown in Figure 22. Same measurements are 
performed as for other NPs. The clear difference can be seen in the fluorescence emission spectra 
between the control liposome and magnetic NPs loaded liposome. 
 
Figure 22 Static fluorescence emission measurements of (a) control liposome, no NP; (b) 
magnetic NPs (Fe3O4)-loaded liposome, before/after exposure to pulsed magnetic field and 
after the release of all dye as model drug using Triton X-100. Reprinted with permission 
from ref.39 Copyright (2014) American Chemical Society. 
 
 
 To quantify the result, the percentage release of the drug is calculated. The percentage 
release of the drug is calculated from the integrated fluorescence intensity of the emission 
spectra. The calculated surface areas under the emission spectra are used to calculate the 
percentage release as: 
%𝒓𝒆𝒍𝒆𝒂𝒔𝒆 =
𝑺𝑨𝑨𝑴𝑭 − 𝑺𝑨𝑩𝑴𝑭
𝑺𝑨𝑨𝑻 − 𝑺𝑨𝑩𝑴𝑭
×𝟏𝟎𝟎 
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where SAAMF is the surface area after exposure to magnetic field, SABMF is the surface area 
before exposure to magnetic field, SAAT is the surface area after the addition of Triton X-100. 
The calculated % releases for control liposomes and Fe3O4 NPs loaded liposomes are tabulated 
in Table 4-2. 
 
Samples SABMF SAAMF SAAT % release 
Liposome 1.22 × 106 1.27 × 106 1.07 × 107 0.12 
Liposome with 
Fe3O4 
2.13 × 106 2.96 × 106 1.20 × 107 8.40 
Table 4-2 Drug Release Data for Control and Magnetic NPs Loaded Liposomes. Reprinted 
with permission from ref.39 Copyright (2014) American Chemical Society. 
 
 
The same experiment is repeated as described above with the hydrophobic, hydrophilic, 
and amphiphilic peptide-coated Fe3O4 NPs, since depending on the surface property of NPs, the 
position of the NPs in the liposomes is fixed. The % releases of drug are calculated which are 
given in the following Table 4-3. The percentage releases with hydrophilic and amphiphilic 
peptide-coated Fe3O4 NPs are almost the same. 
 
Samples SABMF SAAMF SAAT % release 
Hydrophobic  4.61 × 106 4.77 × 106 1.07 × 107 0.24 
Hydrophilic  5.50 × 106 7.28 × 106 5.00 × 107 3.57 
Amphiphilic  2.77 × 106 4.52 × 106 5.09 × 107 3.63 
Table 4-3 Drug Release Data for Hydrophobic, Hydrophilic and Amphiphilic Peptide 
Coated Fe3O4 NPs Reprinted with permission from ref.39 Copyright (2014) American 
Chemical Society. 
 
 
The percentage release with hydrophobic peptide-coated Fe3O4 NPs is comparatively 
small. This indicates that the hydrophobic peptide-coated Fe3O4 NPs are not incorporated in the 
liposomes because of the surface property of NPs. As it has been shown above, when liposomes, 
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filled with magnetic nanoparticles, are exposed to a short magnetic pulse, model drug molecules 
are released quickly from the liposomes. In a recent study, Hu et al.,69 have demonstrated that 
application of magnetic pulses in the presence of magnetic nanoparticles leads to ultrasound 
generation. They used the resulting ultrasound for imaging purposes to reconstruct an image of 
an object filled with magnetic nanoparticles. Their observation is relevant to this work because 
ultrasound is also commonly used on liposomes to release their content.70 To explore if 
ultrasound is generated from our magnetic pulses, iron oxide magnetic nanoparticles were 
exposed to pulsed magnetic fields. In order to assess accurately if the homogeneous or the 
inhomogeneous magnetic fields are more effective to generate ultrasound, two electromagnets 
have been developed that are very similar in construction. Detailed construction and properties of 
the two electromagnets build is described in Chapter 2.6. The sketch of the first magnet consists 
of an anti-Helmholtz coil shown in Figure 23 A and B to produce the large inhomogeneous 
magnetic field on the order of 400 T/m in a 3 mm center part of the coil. 
 In an anti-Helmholtz coil the winding of the coil pairs are in opposition to produce the 
large inhomogeneous magnetic fields. The second coil (Helmholtz coil) is also prepared with 
opposite winding that results in ∼15 T homogeneous magnetic field in the full length of the coil 
(∼50 mm). The magnetic field of the Helmholtz coil has been measured by optical method from 
the Faraday rotation of a small Pyrex rod (Figure 23-C). To quantify the amount of ultrasound 
the concentration of the nanoparticles is varied inside a glass tube that is attached to a 
commercially available hydrophone (BII-7011 from Benthowave Instrument Inc.) as is shown in 
Figure 23-D. 
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Figure 23 (A) Sketch of anti-Helmholtz coil to produce large magnetic field gradient. (B) 
Picture of the finished electromagnet. (C) Measured magnetic pulse by Faraday rotation of 
Pyrex glass. (D) Picture of the experimental apparatus used to detect ultrasound generated 
from pulsed magnetic fields in the presence of magnetic nanoparticles. Reprinted with 
permission from ref.39 Copyright (2014) American Chemical Society. 
 
 
In order to accurately assess the amount of ultrasound from the magnet, the signal from 
the hydrophone is recorded as a function of iron oxide concentration including the water as a 
reference. Figure 24 summarizes the results from the experiments to assess ultrasound generation 
from magnetic nanoparticles. Figure 24-A shows that current derivative as a function of time 
along with the hydrophone signal for water and iron oxide magnetic nanoparticle solution. 
 The presented results are for the Helmholtz coil, but very similar results are obtained for 
the anti-Helmholtz coil as well. The ultrasound power is calculated from the Fourier transform 
power coefficient of the actual signal. Figure 24-B shows the Fourier power coefficients for the 
time-dependent signal from water and from iron oxide NP solutions with increasing 
concentrations. The integrated power coefficients are plotted against the concentration of 
nanoparticles (shown in Figure 24-C). 
 
55 
 
Figure 24 (A) Hydrophone signal from iron oxide NP, water in homogeneous magnetic 
field. As a reference the current derivative of the coil is shown. (B) Fourier power 
coefficient of the time-dependent signal of the NPs in homogeneous magnetic fields. (C) 
Concentration dependence of the ultrasound signal for the homogeneous and 
inhomogeneous magnetic field. The 100% concentration corresponds to the 0.31 volume% 
of EMG 607 iron oxide 15 nm in diameter NPs from Ferrotech Corporation. Reprinted 
with permission from ref.39 Copyright (2014) American Chemical Society. 
 
 
From these results, it is clear that magnetic nanoparticles generate a significant amount of 
ultrasound whether the magnetic field is homogeneous or inhomogeneous. Ultrasound is 
commonly used to disrupt the membranes of liposomes; therefore, we propose that the 
ultrasound generation process from the magnetic nanoparticles residing inside the liposomes is 
the important underlying mechanism for the disruption of lipid bilayers. The results indicate that 
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both magnets produce ultrasound that is significant compared to the water background at 
frequencies corresponding to the frequency of the pulsed magnet (∼30 kHz). In the previous 
study by Hu,69 the primary mechanism for ultrasound generation was the linear acceleration of 
magnetic nanoparticles in the inhomogeneous magnetic fields; however, here we observe that the 
homogeneous magnetic fields also produce a significant amount of ultrasound. It appears that at 
lower concentrations the inhomogeneous magnetic field has a larger contribution to the 
ultrasound generation. (Note that the inhomogeneous magnetic field only impacts 3 mm center 
part of the coil and the homogeneous magnetic field affects the entire length of the coil.) While 
Hu et al. proposed that only inhomogeneous magnetic fields result in noticeable amount of 
ultrasound, the data here indicate that homogeneous magnetic fields can also result in ultrasound. 
The literature indicates71 that in strong magnetic fields the magnetic nanoparticles form chains of 
magnetic beads72 and during this process the displacement of liquid results in ultrasound 
generation. When the magneto liposomes are exposed to magnetic fields, due to the relatively 
large concentration of magnetic nanoparticles inside the liposome, the generated ultrasound can 
significantly contribute to the drug release observed under these experimental conditions. 
 
 
 4.3 Conclusions 
 
Here the fast release of model drug molecules (MgSO4 and 5(6)-carboxyfluorescein) from 
magneto liposomes loaded with Fe3O4 NPs or FePt nanoparticles is demonstrated with the help 
of strong magnetic pulse(s). The experiments indicate that ultrasound is generated from magnetic 
nanoparticles in the presence of pulsed magnetic fields, which is proposed to play a key role in 
the release of the drug molecules from magneto liposomes. The process can be further optimized 
to maximize the amount of drug release based on the solubility of MNPs and the ligand coating 
of the nanoparticles, but no major difficulty is anticipated. 
Potential Applications: (1) Instantaneous delivery of drugs with both temporal and spatial 
precision. (2) Delivery of therapeutic agents for cancer therapy. (3) Delivery of painkiller drug 
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locally following the injection of the drug loaded into magneto liposomes via intravenous 
therapy. (4) Experimental tool to induce instant repeated physiological changes from drugs, 
therefore allowing kinetic studies in living systems. (5) Release of radiation-preventive drugs 
from magneto liposomes induced by the strong electromagnetic field from a nuclear explosion. 
(6) Manipulating/modulating cellular permeability via mechanical force from the pulsed 
magnetic fields. 
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Chapter 5 - Magnetic Field Induced Ultrasound from Colloidal 
Superparamagnetic Nanoparticles 
 
 5.1 Introduction 
 
In a recent study, Kinsohita et al.73 have shown that the blood-brain barrier can be made 
penetrable for drug molecules via application of focused ultrasound. A crucial barrier for more 
effective use of the blood-brain barrier opening is the relatively low penetration of ultrasound via 
the skull.74 This has been achieved using hundreds of transducers at very low frequency as a 
phased array, and clinical prototypes are available and under trial. To avoid unintended 
absorption and overheating of the scalp, a hemispherical phased array applicator with hundreds 
of elements operating at low frequency has been designed and successfully demonstrated within 
a small group of patients.75 An alternative means of generating the ultrasound may provide a 
simplified means for inducing ultrasound within the brain and other deep-seated targets. Here the 
ultrasound generation is investigated from pulsed magnetic fields with the help of colloidal iron 
oxide nanoparticles. The advantage of ultrasound generated from magnetic fields is that the 
magnetic fields do not suffer the same attenuation as ultrasound through bones, soft tissue or air, 
and nanoparticles can be successfully delivered to various places in the human body. Recently, 
Hu et al.69 have demonstrated that ultrasound can be generated via application of pulsed 
magnetic fields with the help of magnetic nanoparticles (mixture of Fe2O3 and Fe3O4). Hu et al. 
used the ultrasound for imaging purposes from the magnetic nanoparticles. Their work 
confirmed that ultrasound can be generated from the acceleration of magnetic nanoparticles in 
inhomogeneous magnetic fields. In a similar theoretical work, Carrey et al. have shown that the 
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effect is maximized and better controlled if a static magnetic field is superimposed on an 
alternating gradient.76 Another important ultrasound generation mechanism in bulk magnetic 
materials is the magnetostriction effect.77 Magnetostriction is a well-known effect of 
ferromagnetic materials to produce significant amount of strain when exposed to magnetic fields. 
The strain induced due to magnetic domain wall movement leads to significant amount of 
volume change, similar to the piezoelectric effect in ultrasonic transducers. The typical volume 
change of ferrous materials is on the order of 10−5; e.g., the magnetostriction coefficients for 
Fe3O4 and γ-Fe2O3 are 1.6 × 10−5 and 0.7 × 10−5, respectively.78 This coefficient can be as high 
as 0.2% e.g. in Ni2MnGa
79 and in TbxDy1−xFe2.
80 Here, it is demonstrated that not only bulk 
materials, but also colloidal ferrofluids are capable of producing ultrasound. The ultrasound 
generated in this work is in agreement with the effect described by Hu et al.69 They have shown 
that the ultrasound is generated in the inhomogeneous magnetic field; however, some ultrasound 
could also be observed as a result of the homogeneous magnetic field via the magnetostriction 
effect. 
Detailed information about the construction of Helmholtz and anti-Helmholtz coils used 
in these experiments is presented in section 2.6 and 2.7. 
 
 5.2 Ultrasound Measurement from Strong Magnetic Pulses 
 
In this study, the acoustic pressure generated from magnetic nanoparticles is investigated in the 
presence of pulsed magnetic fields. A glass capillary tube is filled with EMG 607 ferrofluid and 
exposed to homogeneous and inhomogeneous pulsed magnetic fields. Sound in the magnetic 
fluid is detected using a hydrophone integrated at the end of the glass capillary tube. Figure 25 
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shows the hydrophone signal in the presence of pulsed homogeneous magnetic fields when the 
dispersion of iron oxide nanoparticles is placed in the glass capillary tube.  The distance of the 
detector from the pulse magnet is 6 in., and the concentration of the ferrofluid is 0.5 vol %. The 
graph also shows the current derivative signal from the magnetic field (as a reference) and the 
detected signal of the hydrophone in water in the absence of the nanoparticles. The signals are 
shifted for better visibility. Please note that there is no negative pressure present. 
 
 
Figure 25 Detected ultrasonic signal from ferrofluid EMG 607 in homogeneous magnetic 
pulse with the current derivative signal from the magnetic field and the detected signal of 
the hydrophone in water in the absence of the nanoparticles. Reprinted with permission 
from ref.48 Copyright (2016) American Chemical Society. 
 
The initial pattern of the sound wave agrees well with the pattern observed from the 
pulsed magnetic field. When the tube is not filled with liquid, no appreciable amount of signal is 
observed from the pulsed magnetic fields, which rules out electrical interference from the driving 
circuit of the pulsed magnet. Notice that there is some signal detected from the water itself (see 
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also Figure 25) due to homogeneous strong pulsed magnetic fields, but no high frequency 
component is present. This is likely is due to some heating effects in the glass capillary tube 
and/or water itself. For the rest of the discussion, the water signal is subtracted from the 
ferrofluid signal to accurately gage the amount of high frequency sound generated from the 
nanoparticles.  
The ultrasound from the nanoparticle dispersion exhibits strong concentration 
dependence. In order to accurately assess the amount of the ultrasound present, the time-domain 
signal is analyzed with Fourier analysis. The power coefficient of the concentration dependence 
is plotted against frequency, which shows a strong peak corresponding to the frequency of the 
magnetic field (∼30 kHz) used in the experiment. This frequency component is missing from the 
water only sample, but it is present with increasing magnitude when the ferrofluid concentration 
is increased (Figure 26).  
 
Figure 26 Fourier transform power spectrum of the detected ultrasonic signal from 
ferrofluid EMG 607 in homogeneous magnetic pulse. Reprinted with permission from ref.48 
Copyright (2016) American Chemical Society. 
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In Figure 26 is presented the Fourier transform power spectrum of the detected ultrasonic 
signal from ferrofluid EMG 607 in homogeneous magnetic pulse. The distance of the detector 
from the pulse magnet is 6 in. Increasing the concentration of the ferrofluid results in increased 
power coefficient at around 30 kHz. The power coefficient at 30 kHz in water is taken as the 
baseline signal. In addition to the main component of the signal at around 30 kHz, other low-
frequency components are present, probably due to secondary effects such as heating from 
ultrasound and direct heating from the Brownian relaxation of magnetic nanoparticles.81  
The ultrasonic signal was found to be inversely dependent with distance, with increasing 
amplitude of the 30 kHz component as the distance between and the magnet and the hydrophone 
was decreased. The attenuation of the ultrasonic signal is expected due to the loss of energy of 
sound waves and the organization of the ferrofluid.82 Therefore, to accurately estimate the 
induced ultrasound signal, the ultrasonic signal is detected at various distances from the pulsed 
magnet. The ultrasound generated at zero distance is calculated from linear extrapolation of the 
distance dependent data (not shown). A comparison of the magnitude of ultrasound generated 
from inhomogeneous and homogeneous magnetic field is shown in Figure 27.  
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Figure 27 Comparison of the relative ultrasound generated from homogeneous and 
inhomogeneous magnetic field as a function of the ferrofluid concentrations. Reprinted 
with permission from ref.48 Copyright (2016) American Chemical Society. 
 
Surprisingly, the anti-Helmholtz coil generates less ultrasound pulse than the Helmholtz 
coil when the current in the coils are the same. Although the anti-Helmholtz coil has higher peak 
magnetic field gradient, it has lower average magnetic field gradient than the Helmholtz coil 
(Table 5-1). 
 
 Pulsed coils AC coils 
Helmholtz Anti-Helmholtz Helmholtz Anti-Helmholtz 
Peak Magnetic 
field 
15 T 5 T 2.7 mT 1.9 mT 
Average 
Magnetic field 
4.97 T 1.57 T 1.1 mT 0.7 mT 
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Peak Magnetic 
field gradient 
321 T/m 475 T/m 0.138 T/m 0.221 T/m 
Average 
Magnetic field 
gradient 
0.173 T/m 0.168 T/m 0.049 T/m 0.064 T/m 
Estimated Peak 
Force on 10 nm 
Particle 
1.46 × 10-18 N 2.17 × 10-18 N 6.31 × 10-22 N 1.01 × 10-21 N 
Estimated 
Average Force 
on 10 nm 
Particle 
7.92 × 10-22 N 7.69 × 10-22 N 2.24 × 10-22 N 2.92 × 10-22 N 
Measured max 
Pressure 
334 Pa 294 Pa 10 Pa (at 200 
kHz) 
18 Pa (at 200 
kHz) 
Particle 
concentration 
5.8 × 1015 NP/ml 5.8 × 1015 NP/ml 3.8 × 1016 NP/ml 3.8 × 1016 NP/ml 
Measured 
force/particle 
1.18 × 10-18 N 1.04 × 10-18 N 6.9 × 10-21 N 1.2 × 10-20 N 
Table 5-1 Summary of the Calculated Coil Parameters, the Measured Pressure, and the 
Estimated and Measured Forces Acting on the EMG 607 Magnetic Nanoparticles.  
Reprinted with permission from ref.48 Copyright (2016) American Chemical Society. 
 
The data in Figure 27 also shows that the ultrasound pressure will decrease with 
increasing concentrations of nanoparticles, which could be the result of particle aggregation in 
external magnetic fields.83 Consistent with this argument, it has been observed that in some of 
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the experiments after application of several magnetic pulses, the ferrofluid becomes destabilized 
and the particles in the dispersion are settled at the bottom of the tube.  
 
 5.3 Frequency-Dependent Ultrasound Measurements from Small Amplitude 
AC Magnetic Fields 
 
In the second part of the experiment series, the frequency of the ultrasound is investigated at low 
magnetic field amplitude. The advantage of low magnetic field amplitude is the less likelihood of 
aggregation of the colloidal magnetic nanoparticles,84 and the smaller amount of residual heating 
of the water itself as in the pulsed magnetic field experiments. Similar to the first part of the 
experiments, the ultrasound from colloidal magnetic nanoparticles is measured in two types of 
coils - in a Helmholtz coil and in an anti-Helmholtz coil – to assess the relative importance of the 
inhomogeneous and homogeneous magnetic fields on the colloidal dispersion of magnetic 
nanoparticles for ultrasound generation. The resulting data are shown in Figure 28.  
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Figure 28 Frequency-dependent ultrasound from EMG 607 magnetic nanoparticle 
dispersion in homogeneous and inhomogeneous magnetic fields. The ultrasound pressure is 
normalized to the coil current to ensure that the ultrasound is compared at the same 
magnetic fields at all frequencies. Reprinted with permission from ref.48 Copyright (2016) 
American Chemical Society. 
 
 
As it can be seen in Figure 28, the anti-Helmholtz coil produce approximately twice the 
magnitude of ultrasound pressure as the Helmholtz coil. This strongly suggests that at these low 
magnetic field amplitudes the inhomogeneous magnetic field is key for the mechanism of 
ultrasound generation in EMG 607 magnetic dispersion. The figure also shows the data when the 
colloidal dispersion of magnetic nanoparticles is moved out of the magnets exhibiting minimal 
ultrasound generation. Interestingly, there is significant amount of ultrasound generated in both 
coils even at 500 kHz. The frequency dependence suggests that the ultrasound levels off as the 
frequency is increasing. Because in this experiment, the hydrophone is several inches away from 
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the ultrasound source, the frequency drop off the ultrasound is consistent with the attenuation of 
the ultrasound at higher frequencies. Based on these data, it is predicted that there is still 
significant ultrasound generated beyond 500 kHz frequencies.  
 
 5.4 Mechanism of ultrasound generation 
 
There are two possible mechanisms for ultrasound generation in the ferrofluid. The first 
mechanism is the translational motion of the magnetic nanoparticles in the inhomogeneous 
magnetic fields as described by Hu et al.69 The second mechanism is the magnetostriction effect 
(change of shape due to magnetization) of the magnetic nanoparticles in the homogeneous 
magnetic fields. This latter mechanism is well-known for the generation of ultrasound in the 
bulk. From these experiments the magnetostriction coefficient is calculated from the pulsed 
experiments by converting the voltage signal from the hydrophone to pressure using the 
sensitivity of the hydrophone. In order to accurately estimate the amount of ultrasound generated 
at the center of magnet, the initial ultrasound amplitude is extrapolated to the center of the 
magnet along with the error bars from the fit. The pressure is then converted to volume change 
from the known compressibility of the water (4.4 × 10−10 Pa−1).85 The calculated volume change 
is then normalized to the volume of the nanoparticles present in the magnetic field directly 
yielding the volume magnetostriction coefficient. The experiments use relatively large magnetic 
fields that ensures that the measurement is performed at magnetic fields where the iron oxide 
reaches its saturation magnetization. As shown in Figure 29, the calculated magnetostriction 
coefficient is comparable to the bulk magnetostriction coefficient of iron oxide; however, the 
magnetostriction coefficient is somewhat larger magnitude than the bulk magnetostriction 
coefficient of bulk iron oxide. 
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Figure 29 Calculated volume magnetostriction coefficient of iron oxide particles from the 
compressibility of water (4.6 × 10−10 Pa−1) as a function of nanoparticle concentration. The 
bulk magnetostriction coefficient of iron oxide is also indicated in the graph by the dashed 
line. Reprinted with permission from ref.48 Copyright (2016) American Chemical Society. 
In addition, the magnetostriction coefficient shows a concentration dependence. These 
experiments show an inverse relationship between the nanoparticle concentrations vs the 
magnetostriction coefficient for iron oxide. At higher concentration of the ferrofluid, the 
response becomes more bulklike. The deviation of the magnetostriction coefficient especially at 
lower concentrations becomes significant. We hypothesize that the difference between the 
observed magnetostriction coefficient and the magnetostriction coefficient calculated from the 
experiments has to come from a different mechanism. We propose that at lower concentration of 
the colloidal dispersion of magnetic nanoparticles the particles are less confined to move around, 
and ultrasound generation from the translation motion of the magnetic particles becomes more 
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effective. This additional motion of the particles in the magnetic field gradient becomes 
dominant under these conditions for ultrasound generation.  
The translational displacement of the magnetic nanoparticles in the presence of 
inhomogeneous magnetic fields is primarily controlled by the presence of magnetic field gradient 
and the magnetic field. According to Cao et al.,86 the magnetic force (?⃗?𝑚) that a spherical 
particle experiences in a colloidal dispersion, after reaching terminal speed due to solvent drag 
forces, can be divided into two regions. At low magnetic fields, when 𝐻𝑎⃗⃗⃗⃗⃗⃗ <  
𝜒+3
3𝜒
𝑀𝑠𝑎𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ , and 𝐹𝑚⃗⃗ ⃗⃗ ⃗ =
𝑉𝑚
𝜇0
3𝜒
𝜒+3
(𝐻𝑎⃗⃗⃗⃗⃗⃗ ∇)𝐻𝑎⃗⃗⃗⃗⃗⃗ , where 𝜇0 is the vacuum permeability, 𝑉𝑚 is the particle volume, 𝜒 is the 
magnetic susceptibility, 𝑀𝑠𝑎𝑡 is the saturation magnetization, and 𝐻𝑎 is the magnetic field. At 
high magnetic fields, 𝐹𝑚⃗⃗ ⃗⃗ ⃗ =
𝑉𝑚
𝜇0
(𝑀𝑠𝑎𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ∇)𝐻𝑎⃗⃗⃗⃗⃗⃗  when 𝐻𝑎⃗⃗⃗⃗⃗⃗ ≥  
𝜒+3
3𝜒
𝑀𝑠𝑎𝑡⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ ⃗⃗ . The EMG 607 colloidal 
solution has a saturation magnetization at 11 mT. This low saturation magnetization strongly 
suggests that in the strong pulsed magnetic field experiments the magnetic force (pressure) 
produced from the inhomogeneous magnetic field will be linearly proportional to the external 
magnetic field. As shown in Figure 30, in the pulsed experiments the pressure is directly 
proportional to the magnetic field.  
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Figure 30 Comparison of the magnetic field and the pressure signal in the Helmholtz coil. 
Similar results can be obtained for the anti-Helmholtz coil. The result shows that the 
induced pressure is directly proportional to the magnetic field in this case. Reprinted with 
permission from ref.48 Copyright (2016) American Chemical Society. 
 
In the AC experiments (Figure 31), our calculation shows that the magnetic field is 
between 2 and 3 mT, which is comparable to, but less than, the saturation magnetization; 
however, due to the strong decrease of the susceptibility of the colloidal magnetic particles at 
higher frequencies, we expect to observe that the pressure will be linearly proportional to the 
magnetic field. 
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Figure 31 Dependence of ultrasound at 200 kHz on coil current from EMG 607 magnetic 
nanoparticle dispersion in two different coils in the frequency-dependent ultrasound 
measurements. Reprinted with permission from ref.48 Copyright (2016) American 
Chemical Society. 
 
As shown in Figure 31, the pressure signal from the ultrasonic sensor is also linear with 
respect to the coil current (magnetic field). The spherical magnetic nanoparticle will experience a 
force in the direction of the magnetic field gradient. It is important to point out that both the 
Helmholtz coil and the anti-Helmholtz coil produce a significant amount of magnetic field 
gradients. Table 5-1 summarizes the calculated and measured forces in these experiments. The 
force that the hydrophone experiences is the result of the pressure wave produced in different 
parts of the colloidal dispersion inside the coils. Forces estimated based on both the peak 
magnetic field gradient and the average magnetic field gradient of the particles in the magnetic 
coil are shown in Table 5-1. The measured forces/magnetic particles are calculated from the 
experimentally measured ultrasonic pressures. The data show that the pressure calculated from 
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experiments agrees very well with the estimated pressures expected based on the available 
magnetic field gradient. The estimated force is comparable to the values listed in the literature 
for a similar sized magnetic nanoparticles.76 There are several biocompatible colloidal 
nanoparticle systems that are already being utilized for magnetic hyperthermia treatments.54b 
Modifying these nanoparticles systems to produce ultrasound for various purposes will be a 
simple modification of the type of magnetic field generators used to reach to higher magnetic 
fields. Nonthermal effects of ultrasound include cavitation, which is employed for delivery of 
drugs and other small molecules to cells.87 The threshold for inducing cavitation required for 
adjusting membrane permeability is on the order of ∼450 kPa;88 this threshold may be reduced in 
the presence of microbubbles and other cavitation nuclei. Other nonthermal bioeffects of low 
intensity ultrasound may be achieved at lower intensities. With greater driving current, the 
acoustic intensities generated by the proposed technique have application for localized 
modification of the permeability of cell membranes for delivery of therapeutic agents and 
stimulating bioeffects. We anticipate that the ultrasound from magnetic nanoparticles will be 
able to effectively manipulate the permeability of small molecules across lipid bilayers.89 
 
 5.5 Conclusion 
 
In this chapter, the ultrasound is detected from the pulsed magnetic from colloidal magnetic 
nanoparticles. Comparison of the data from homogeneous and inhomogeneous magnetic fields 
suggests that the ultrasound is driven primarily by the presence of the inhomogeneous magnetic 
fields. 
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Chapter 6 - Summary 
 
In summary, this thesis presented the latest advancements in drug delivery systems, (including its 
underlying mechanics) while focusing on attaining drug release from magneto liposomes upon 
exposure to pulsed magnetic field. 
Magneto liposomes are studied as a drug delivery platform, including the synthesis of 
paramagnetic nanoparticles and magneto liposomes. Upon confirming drug release from 
magneto liposomes, several potential applications arise including: (1) Instantaneous delivery of 
drugs with both temporal and special precision. (2) Delivery of therapeutic agents for cancer 
therapy. (3) Delivery of pain killer drug locally following the injection of the drug loaded into 
magneto liposomes via intravenous therapy. (4) Experimental tool to induce instant repeated 
physiological changes from drugs, therefore allowing kinetic studies in living systems. (5) 
Manipulating/modulating cellular permeability via mechanical force from the pulsed magnetic 
fields.  
In addition, the construction and operation of a novel Helmholtz are demonstrated to 
generate strong rotating magnetic field. The design shows scalability by manipulating several 
factors: increasing the number of plates used to construct the coils, reducing its dimensions, and 
increasing discharge voltage. 
Finally, the ultrasound is detected from the pulsed magnetic from colloidal magnetic 
nanoparticles. Comparison of the data from homogeneous and inhomogeneous magnetic fields 
suggests that the ultrasound is driven primarily by the presence of the inhomogeneous magnetic 
fields. Confirming that ultrasound is generated from colloidal paramagnetic nanoparticles, will 
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have applications toward the acoustic induction of bioeffects in cells and manipulating the 
permeability of biological membranes. 
Although attaining drug release from magneto liposomes upon exposure to pulsed 
magnetic fields has been successful, several improvements can be made: (1) relocating the 
magnetic nanoparticles outside of the liposomes using a chemical linker. Since ultrasounds are 
produced from magnetic nanoparticles, relocating the magnetic nanoparticles outside of the 
liposome can reduce the complexity of the protocol for synthesis of liposomes. In the same time, 
the interior of the liposome will be “available”, for a larger amount of drug to be incorporated. In 
addition, placing the magnetic nanoparticles outside the liposomes will result in less aggregation 
and a higher number of nanoparticles available per liposome.  (2) Improving magnetic 
nanoparticle functionality with gold. Iron oxide gold coated nanoparticles will significantly 
improve the versatility of the magneto liposome systems by providing a solid and well-studied 
platform to bind ligands to the nanoparticles. In addition, a recent study,90 proves that, when 
cytotoxicity of HepG2 malignant tumor cells is assessed, gold coated iron oxide nanoparticles 
show 52% less toxicity compared to iron oxide nanoparticles. 
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